ZOLL Itamar logo

Drawing attention to another risk during sleep apnea testing

Home sleep apnea testing

The link between atrial fibrillation (AFib) and sleep apnea has been clinically established1

ZI sl1_iconsAsset_50pct_v2_lrg
ArrLP_C_Asset_carousel1
ArrLP_C_Asset_carousel3
ArrLP_C_Asset_carousel4
ArrLP_C_Asset_carousel5

Introducing the NEW WatchPAT® Arrhythmia Detection Feature that can detect AFib events and premature beats*

ArrLPAsset_icon_fda
FDA-cleared to identify AFib events and premature beats
ArrLPAsset_icon_process
Proprietary, cutting-edge technology that has been enhanced over the years
ArrLPAsset_icon_reports
Automatically generated all-in-one sleep & cardiac rhythm analysis report
EXPECT MORE

New Arrhythmia Detection Feature

  • Identifies arrhythmic events that occur during sleep
  • Flags at-risk patients, supporting the physician in deciding if further investigation is needed
  • Proven to accurately detect major arrhythmias in a multicenter study6*
*The WatchPAT is not intended to be used as a diagnostic device for any cardiac arrhythmia and is not intended to replace traditional methods of diagnosis for cardiac arrhythmias. In cases where the longest AFib episode detected is shorter than 60 seconds, review of the PAT® signal for an irregularly irregular rhythm in the location of the episode is recommended. The WatchPAT may not detect short AFib episodes (<60 seconds).

Expect more from your WatchPAT HSAT.

Diagnose sleep apnea AND help uncover arrhythmias at the same time with WatchPAT.

Want to know more? Just complete the form below.

*Required

Copyright © 2023 ZOLL Itamar. All rights reserved. WatchPAT and PAT are trademarks or registered trademarks of ZOLL Itamar, a subsidiary of ZOLL Medical Corporation, in the United States and/or other countries. All other trademarks are the property of their respective owners.

References: 1. Gami AS, Pressman G, Caples SM, et al. Association of atrial fibrillation and obstructive sleep apnea. Circulation. 2004;110(4):364-367. 2. Yeghiazarians Y, Jneid H, Tietjens JR, et al. Obstructive sleep apnea and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021;144(3):e56-e67. 3. Højager A, Schoos MM, Tingsgaard PK, Bock TG, Homøe P. et al. Prevalence of silent atrial fibrillation and cardiovascular disease in patients with obstructive sleep apnea. Sleep Med. 2022;100:534-541. doi: 10.1016/j.sleep.2022.10.002 4. Colilla S, Crow A, Petkun W, et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013;112(8):1142-1147. doi: 10.1016/j.amj-card.2013.05.063 5. Shukla A, Aizer A, Holmes D, et al. Effect of obstructive sleep apnea treatment on atrial fibrillation recurrence: a meta-analysis. JACC Clin Electrophysiol. 2015;1(1-2):41-51. doi:10.1016/j.jacep.2015.02.014 6. Pillar G, Berall M, Berry RB, et al. Detection of common arrhythmias by the Watch-PAT: expression of electrical arrhythmias by pulse recording. Nat Sci Sleep. 2022;14:751-763. doi: 10.2147/NSS.S359468

Skip to content